Literature DB >> 10739329

Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia.

P E Keck1, S L McElroy, S M Strakowski, C A Soutullo.   

Abstract

Psychosis occurs commonly in patients with mood disorders and has traditionally been treated with typical antipsychotics. Exposure to typical antipsychotics poses a risk for the emergence of tardive dyskinesia. Atypical antipsychotics may have advantages over typical agents in the treatment of patients with mood disorders complicated by psychotic features. The studies of typical and atypical antipsychotics in the treatment of mood disorders were reviewed. Similarly, studies regarding the risk of tardive dyskinesia from typical and atypical agents in patients with mood disorders were surveyed. Typical and atypical antipsychotics appear to be comparably effective in the treatment of acute mania. Limited data regarding these medications in psychotic depression are available. Advantages of atypical antipsychotics include, for most agents, minimal extrapyramidal and prolactin effects, inherent thymoleptic activity, and lower rates of tardive dyskinesia. Atypical antipsychotics appear to have a number of advantages over typical agents in the treatment of patients with psychotic mood disorders.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739329

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

1.  Lithium cation enhances anion binding in a tripodal phosphine oxide-based ditopic receptor.

Authors:  Jesse V Gavette; Juven Lara; Orion B Berryman; Lev N Zakharov; Michael M Haley; Darren W Johnson
Journal:  Chem Commun (Camb)       Date:  2011-06-07       Impact factor: 6.222

2.  The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C.

Authors:  Caleb C Lord; Steven C Wyler; Rong Wan; Carlos M Castorena; Newaz Ahmed; Dias Mathew; Syann Lee; Chen Liu; Joel K Elmquist
Journal:  J Clin Invest       Date:  2017-08-14       Impact factor: 14.808

3.  Sigma receptors [σRs]: biology in normal and diseased states.

Authors:  Colin G Rousseaux; Stephanie F Greene
Journal:  J Recept Signal Transduct Res       Date:  2015-06-09       Impact factor: 2.092

4.  A randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder.

Authors:  William V Bobo; Richard A Epstein; Alan Lynch; Tynya D Patton; Nicholas A Bossaller; Richard C Shelton
Journal:  Clin Neuropharmacol       Date:  2011 Nov-Dec       Impact factor: 1.592

Review 5.  Tiagabine for acute affective episodes in bipolar disorder.

Authors:  Akshya Vasudev; Karine Macritchie; Sanjay K Rao; John Geddes; Allan H Young
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 6.  Comparative efficacy and tolerability of drug treatments for bipolar disorder.

Authors:  S M Strakowski; M P DelBello; C M Adler
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 7.  Olanzapine: a review of its use in the treatment of bipolar I disorder.

Authors:  N Bhana; C M Perry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

8.  The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression.

Authors:  Daniel M Blumberger; Benoit H Mulsant; Dora Kanellopoulos; Ellen M Whyte; Anthony J Rothschild; Alastair J Flint; Barnett S Meyers
Journal:  J Clin Psychopharmacol       Date:  2013-06       Impact factor: 3.153

9.  Antipsychotics possessing antidepressive efficacy increase Golf protein in rat striatum.

Authors:  Hideki Taoka; Takashi Hamamura; Shiro Endo; Shinji Miyata; Kishio Toma; Takeshi Ishihara; Shigetoshi Kuroda
Journal:  Psychopharmacology (Berl)       Date:  2008-09-06       Impact factor: 4.530

Review 10.  Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence.

Authors:  Chi-Un Pae; Alessandro Serretti; Ashwin A Patkar; Praksh S Masand
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.